Abstract
Uremic patients with hyperlipidemia are classified at high atherogenic risk due to oxidative stress induced by regular hemodialysis process (hemoincompatibility) and a high level of oxidized low-density lipoprotein (ox-LDL). This study aimed to investigate whether LDL apheresis was capable of reducing oxidative and atherogenic markers in uremic patients with hyperlipidemia. We found that oxidative metabolites (methylquanidine, dityrosine, and ox-LDL) and atherogenic markers (lipoprotein (a), LDL, and LDL/HDL ratio) were significantly reduced (P < 0.05) after LDL apheresis. On the other hand, plasma total antioxidant status (TAS) was not influenced after LDL apheresis. Our results suggest that LDL apheresis reduces oxidative and atherogenic markers and do not influence plasma TAS in uremic patients with hyperlipidemia. This may lead to a decreased risk of atherosclerosis in these patients. However, supplementation of dietary proteins may be necessary because of the removal of some “useful” proteins (e.g., albumin and globulin) after LDL apheresis.
Similar content being viewed by others
References
Erlenkotter A, Eudres P, Nederlof B, Homig C, Vieuken J (2008) Score model for the evaluation of dialysis membrane hemocompatibility. Artif Organs 32:962–969
Optrny K Jr, Kurouzzecky A, Polauska K, Mares J, Tomsu M, Bowry SK, Vienken J (2006) Does an alteration of dialyzer design and geometry affect biocompatibility parameters? Hemodial Int 10:201–208
Colli-Benuour EE, Kouidhi B, Dey M, Youues R, Bouaziz C, Achour A (2009) Cytotoxic effects exerted by polyarylsulfone dialyzer membrane depend on different sterilization processes. Int Urol Nephrol Oct 1 [Epub ahead of print]
de Sa HM, Freitas LA, Alves VC, Garcao MF, Rosa MA, Marques AA (2000) Leukocyte, platelet and endothelial activation in patients with acute renal failure treated with intermittent hemodialysis. Am J Nephrol 21:264–273
Banche G, Allizond V, Ciacchino F, Mandras N, Roana J, Bonello F, Belardi P, Tullio V, Merlino C, Carlone N, Cuffini AM (2006) Effect of dialysis membrane biocompatibility on polymorphonuclear granulocyte activity in dialysis patients. Nephrol Dial Transplant 21:3532–3538
Ishigaki Y, Ogihara T, Gao J (2008) Impact of plasma oxidized low-density removal on atherosclerosis. Circulation 118:75–83
Raffaella S, Aldo P (1995) Effect of methylquanidine on rat blood pressure: role of endothelial nitric oxide synthase. Br J Pharm 115:510–514
Winterbourn CC, Parsons-Mair HN, Gebicki S (2004) Requirements for superoxide-dependant tyrosine hydroperoxide formation in peptides. Biochem J 381:241–248
Borberg H (2009) 26 years of LDL-apheresis: a review of experience. Transfus Apher Sci 41:49–59
Mehta PK, Baer J, Nell C, Sperling LS (2009) Low-density lipoprotein apheresis as a treatment option for hyperlipidemia. Curr Treat Options Cardiovasc Med 11:279–288
Kobayashi S (2008) Application of LDL-apheresis in nephrology. Clin Exp Nephrol 12:9–15
Schettler M, Wieland E, Methe H (1998) Activity of free radical scavenging enzymes in red cells and plasma of patients undergoing extracorporeal low-density lipoprotein apheresis. Artif Organs 22:123–128
Schettler V, Methe H, Staschinsky D (1999) Review: the oxidant/antioxidant balance during low density lipoprotein apheresis. Ther Apher 3:219–226
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Chen, TS., Liou, SY., Wu, HC. et al. Low-density lipoprotein (LDL) apheresis reduces atherogenic and oxidative markers in uremic patients with hyperlipidemia. Int Urol Nephrol 43, 471–474 (2011). https://doi.org/10.1007/s11255-010-9722-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11255-010-9722-y